Amido ether substituted imidazoquinolines

Details Amido ether substituted imidazoquinolines Amido ether substituted imidazoquinolines

2001-12-06

2003-12-09

Huang, Evelyn Mei (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S082000

Reexamination Certificate

active

06660747

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to imidazoquinoline compounds that have ether and amido functionality at the 1-position, and to pharmaceutical compositions containing such compounds. A further aspect of this invention relates to the use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals, and in the treatment of diseases, including viral and neoplastic diseases.
BACKGROUND OF THE INVENTION
The first reliable report on the 1H-imidazo[4,5-c]quinoline ring system, Backman et al.,
J. Org. Chem.
15, 1278-1284 (1950) describes the synthesis of 1-(6-methoxy-8-quinolinyl)-2-methyl-1H-imidazo[4,5-c]quinoline for possible use as an antimalarial agent. Subsequently, syntheses of various substituted 1H-imidazo[4,5-c]quinolines were reported. For example, Jain et al.,
J. Med. Chem.
11, pp. 87-92 (1968), synthesized the compound 1-[2-(4-piperidyl)ethyl]-1H-imidazo[4,5-c]quinoline as a possible anticonvulsant and cardiovascular agent. Also, Baranov et al.,
Chem. Abs.
85, 94362 (1976), have reported several 2-oxoimidazo[4,5-c]quinolines, and Berenyi et al.,
J. Heterocyclic Chem.
18, 1537-1540 (1981), have reported certain 2-oxoimidazo[4,5-c]quinolines.
Certain 1H-imidazo[4,5-c]quinolin-4-amines and 1- and 2-substituted derivatives thereof were later found to be useful as antiviral agents, bronchodilators and immunomodulators. These are described in, inter alia, U.S. Pat. Nos. 4,689,338; 4,698,348; 4,929,624; 5,037,986; 5,268,376; 5,346,905; and 5,389,640, all of which are incorporated herein by reference.
There continues to be interest in the imidazoquinoline ring system.
Certain 1H-imidazo[4,5-c]naphthyridine-4-amines, 1H-imidazo[4,5-c]pyridin-4-amines, and 1H-imidazo[4,5-c]quinolin-4-amines having an ether containing substituent at the 1 position are known. These are described in U.S. Pat. Nos. 5,268,376; 5,389,640; 5,494,916; and WO 99/29693.
Despite these attempts to identify compounds that are useful as immune response modifiers, there is a continuing need for compounds that have the ability to modulate the immune response, by induction of cytokine biosynthesis or other mechanisms.
SUMMARY OF THE INVENTION
We have found a new class of compounds that are useful in inducing cytokine biosynthesis in animals. Accordingly, this invention provides imidazo[4,5-c]quinoline-4-amine and tetrahydroimidazo[4, 5-c]quinoline-4-amine compounds that have an ether containing substituent at the 1-position. The compounds are defined by Formulas (I) and (II), which are defined in more detail infra. These compounds share the general structural formula:
wherein X, R
1
, R
2
, and R are as defined herein for each class of compounds having Formulas (I) and (II).
The compounds of Formulas (I) and (II) are useful as immune response modifiers due to their ability to induce cytokine biosynthesis and otherwise modulate the immune response when administered to animals. This makes the compounds useful in the treatment of a variety of conditions such as viral diseases and tumors that are responsive to such changes in the immune response.
The invention further provides pharmaceutical compositions containing the immune response modifying compounds, and methods of inducing cytokine biosynthesis in an animal, treating a viral infection in an animal, and/or treating a neoplastic disease in an animal by administering a compound of Formula (I) or (II) to the animal.
In addition, the invention provides methods of synthesizing the compounds of the invention and novel intermediates useful in the synthesis of these compounds.
DETAILED DESCRIPTION OF THE INVENTION
As mentioned earlier, we have found certain compounds that induce cytokine biosynthesis and modify the immune response in animals. Such compounds are represented by Formulas (I) and (II) as shown below.
Imidazoquinoline compounds of the invention, which have ether and amide functionality at the 1-position, are represented by Formula (I):
wherein:
X is —CHR
5
—, —CHR
5
-alkyl-, or —CHR
5
-alkenyl-;
R
1
is selected from the group consisting of:
—R
4
—CR
3
—Z—R
6
-alkyl;
—R
4
—CR
3
—Z—R
6
-alkenyl;
—R
4
—CR
3
—Z—R
6
-aryl;
—R
4
—CR
3
—Z—R
6
-heteroaryl;
—R
4
—CR
3
—Z—R
6
-heterocyclyl;
—R
4
—CR
3
—Z—H;
—R
4
—NR
7
—CR
3
—R
6
-alkyl;
—R
4
—NR
7
—CR
3
—R
6
-alkenyl;
R
4
—NR
7
—CR
3
—R
6
-aryl;
—R
4
—NR
7
—CR
3
—R
6
-heteroaryl;
—R
4
—NR
7
CR
3
—R
6
-heterocyclyl; and
—R
4
—NR
7
—CR
3
—R
8
;
each Z is independently —NR
5
—, —O—, or —S—;
R
2
is selected from the group consisting of:
-hydrogen;
-alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
-alkyl-Y-alkenyl;
-alkyl-Y-aryl; and
-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
—OH;
-halogen;
—N(R
5
)
2
;
—CO—N(R
5
)
2
;
—CO—C
1-10
alkyl;
—CO—O—C
1-10
alkyl;
—N
3
;
-aryl;
-heteroaryl;
-heterocyclyl;
—CO-aryl; and
—CO-heteroaryl;
each R
3
is ═O or ═S;
each R
4
is independently alkyl or alkenyl, which may be interrupted by one or more —O— groups;
each R
5
is independently H or C
1-10
alkyl;
R
6
is a bond, alkyl, or alkenyl, which may be interrupted by one or more —O— groups;
R
7
is H, C
1-10
alkyl, or arylalkyl; or R
4
and R
7
can join together to form a ring;
R
8
is H or C
1-10
alkyl; or R
7
and R
8
can join together to form a ring;
each Y is independently —O— or —S(O)
0-2
—;
n is 0 to 4; and
each R present is independently selected from the group consisting of C
1-10
alkyl, C
1-10
alkoxy, hydroxy, halogen and trifluoromethyl;
or a pharmaceutically acceptable salt thereof.
The invention also includes tetrahydroimidazoquinoline compounds that bear an ether and amide containing substituent at the 1-position. Such tetrahydroimidazoquinoline compounds are represented by Formula (II):
wherein:
X is —CHR
5
—, —CHR
5
-alkyl-, or —CHR
5
-alkenyl-;
R
1
is selected from the group consisting of:
—R
4
—CR
3
—Z—R
6
-alkyl;
—R
4
—R
3
—Z—R
6
-alkenyl;
—R
4
—CR
3
—Z—R
6
-aryl;
—R
4
—CR
3
—Z—R
6
-heteroaryl;
—R
4
—CR
3
—Z—R
6
-heterocyclyl;
—R
4
—CR
3
—Z—H;
—R
4
—NR
7
—CR
3
—R
6
-alkyl;
—R
4
—NR
7
—CR
3
—R
6
-alkenyl;
—R
4
—NR
7
—CR
3
—R
6
-aryl;
—R
4
—NR
7
—CR
3
—R
6
-heteroaryl;
—R
4
—NR
7
—CR
3
—R
6
-heterocyclyl;
—R
4
—NR
7
—CR
3
—R
8
;
each Z is independently —NR
5
—, —O—, or —S—;
R
2
is selected from the group consisting of:
-hydrogen;
-alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
-alkyl-Y-alkenyl;
-alkyl-Y-aryl; and
-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
—OH;
-halogen;
—N(R
5
)
2
;
—CO—N(R
5
)
2
;
—CO—C
1-10
alkyl;
—CO—C
1-10
alkyl;
—N
3
;
-aryl;
-heteroaryl;
-heterocyclyl;
—CO-aryl; and
—CO-heteroaryl;
each R
3
is ═O or ═S;
each R
4
is independently alkyl or alkenyl, which may be interrupted by one or more —O— groups;
each R
5
is independently H or C
1-10
alkyl;
R
6
is a bond, alkyl, or alkenyl, which may be interrupted by one or more —O— groups;
R
7
is H, C
1-10
alkyl, or arylalkyl; or R
4
and R
7
can join together to form a ring;
R
8
is H or C
1-10
alkyl; or R
7
and R
8
can join together to form a ring;
each Y is independently —O— or —S(O)
0-2
—;
n is 0 to 4; and
each R present is independently selected from the group consisting of C
1-10
alkyl, C
1-10
alkoxy, hydroxy, halogen, and trifluoromethyl;
or a pharmaceutically acceptable salt thereof.
Preparation of the Compounds
Compounds of the invention can be prepared according to Reaction Scheme I where R, R
2
, R
3
, R
4
, X, Z and n are as defined above and R
11
is —R
6
-alkyl, —R
6
-aryl, —R
6
-heteroaryl or —R
6
-heterocyclyl where R
6
is as defined above.
In step (1) of Reaction Scheme I a 1H-imidazo[4,5-c]quinolin-1-yl alcohol of Formula X is alkylated with a halide of Formula XI to provide a 1H-imidazo[4,5-c]quinolin-1-yl ether of Formula XII. The alcohol of Formula X is reacted with sodium hydride in a suitable solvent such as N,N-dimethylformamide to form an alkoxide. Al

Affiliated with

Also associated with

Rating

Amido ether substituted imidazoquinolines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Amido ether substituted imidazoquinolines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amido ether substituted imidazoquinolines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3148522